Ventyx Biosciences Announces $27 Million Strategic Investment …
WEBSAN DIEGO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that Sanofi has agreed to make a $27 million strategic ...
Ventyx Biosciences Announces $27 Million Strategic Investment …
WEB6 days ago · SAN DIEGO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that ...
Investors & News – Ventyx Biosciences, Inc.
WEBJun 11, 2024 · Investors & News. We are a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. Our clinical-stage pipeline includes VTX3232, a Phase 2 ready CNS-penetrant inhibitor of the NLRP3 inflammasome, VTX2735, a Phase 2 ready peripheral inhibitor ...
News Releases - Ventyx Biosciences, Inc.
WEBSep 6, 2024 · Ventyx Biosciences Announces Positive Preclinical Data for CNS-Penetrant NLRP3 Inhibitor VTX3232 Demonstrating Reversal of Obesity and Improvements in Cardiometabolic and Inflammatory Markers. Read more.
Sanofi gains exclusivity rights to Ventyx’s CNS-penetrant drug in …
WEB6 days ago · VTYX. Sanofi will gain exclusivity rights to Ventyx Biosciences’ CNS-penetrant candidate VTX3232 as part of a $27m deal. Under the terms of the agreement, Sanofi will buy 70,601 shares of Ventyx ...
Ventyx Biosciences Shares Rise Premarket on Sanofi Investment
WEB6 days ago · Ventyx said Sanofi is buying 70,601 Series A non-voting convertible preferred shares, each convertible into 100 common shares at $3.82 each, a 66% premium to Friday's closing price of $2.30.
Ventyx Biosciences Announces Positive Preclinical Data for ... - BioSpace
WEBJun 5, 2024 · Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, announced positive preclinical data for its CNS-penetrant NLRP3 inhibitor VTX3232 in murine diet-induced obesity models.
Ventyx Biosciences Announces Positive Results from the
WEBOct 9, 2023 · Topline results are summarized below: 28% of patients on the 60 mg dose and 24% of patients on the 30 mg dose achieved the primary endpoint of clinical remission at Week 13 compared to 11% of...
Ventyx Biosciences Announces $27 Million Strategic ... - BioSpace
WEB6 days ago · Sanofi to receive an exclusive right of first negotiation for Ventyx’s CNS-penetrant NLRP3 inhibitor VTX3232. SAN DIEGO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today ...
Ventyx stock climbs 8% on $27M Sanofi investment
WEB9h. S hares of Ventyx Biosciences (NASDAQ: VTYX) jumped 8% in morning trading Monday on news that Sanofi (NASDAQ: SNY) has made a $27M strategic investment in the company in exchange for a right ...